Home » Archives for l.ferguson@neurotechusa.com
November 8, 2024
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
June 20, 2024
Neurotech Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel)
January 1, 2024
Neurotech Executives Jim Mazzo, Chairman and Rich Small, CEO to Present at Annual J.P. Morgan Healthcare Conference
December 2, 2023
Rich Small, Chief Executive Officer, presents the latest on our Encapsulated Cell Therapy Platform during the Retina Innovation Showcase at OIS XIII Summit
September 13, 2023
Alex Gorsky Appointed to Neurotech’s Board as Lead Director
July 24, 2012
NT-501 Granted Orphan-Drug Designation for Macular Telangiectasia Type 2 (MacTel)
,